Sana Biotechnology, Inc. (NASDAQ:SANA) is a top American penny stock according to analysts. Citi analyst Samantha Semenkow maintained a Buy rating on SANA with a $15 price target, citing the company’s potential in addressing market needs, particularly in Type 1 Diabetes program with promising six-month data. The company also makes progress in its allogeneic CAR-T platform targeting autoimmune diseases and relapsed NHL.

Sana Biotechnology, Inc. (NASDAQ:SANA) focuses on developing engineered cell-based medicines for diseases with unmet needs like type 1 diabetes, autoimmune diseases, and cancer. Despite its potential, other AI stocks offer greater upside potential with less downside risk. Investors looking for undervalued AI stocks can explore other options for better returns.

Read more at Yahoo Finance: Citi Maintained a Buy Rating on Sana Biotechnology (SANA)